These data support the concept that IDH1/2mut gliomas have increased activity in HDAC pathways, and suggests targeting histone acetylation via HDAC inhibitors may exhibit profound effects in IDH1/2mut glioma. Here, HDAC9 is linked to central nervous system cancer.